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responsible for around 2–5% of total hypertensive population.
Among patients with renovascular hypertension (RVH), incidence
of atherosclerotic renal artery stenosis (ARAS) is about 80–90%,
whereasﬁbromusculardysplasia (FMD) is responsible only foraround
10% patients. Intimal ﬁbroplasia occurs in less than 10% of all the
patients with FMD.We report a rare case of 28-year-old ladywho had
newly detected hypertension during 12th week of pregnancy later
leading to intra-uterinedeathof the fetusat28weeksofgestation,and
then she was referred to us for evaluation and management and
found to have intimal ﬁbromuscular dysplasia of renal artery, which
was treated successfully with percutaneous intervention.
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Background: Distal embolization of thrombus during primary PCI
results into reduced myocardial perfusion and poor clinical out-
comes. The objective of our study was to assess the role of manual
thrombus aspiration to improve myocardial perfusion occur dur-
ing primary PCI.
Methods: Single center prospective observation study was under-
taken in a tertiary care hospital. Study was carried out on 104
number of patients presented with STEMI of <12 h duration. Of
which, 52 underwent primary PCI with thrombus aspiration and
remaining were opted for conventional primary PCI. Angiographic
and electrocardiographic signs of myocardial perfusion, as well as
clinical outcomes were assessed. The primary end was corrected
TIMI frame count (cTFC) and secondary end points were ST seg-
ment resolution and mortality at 30 days and 6 months.
Results: A cTFC of<30 occurred in 94.23% of patients in primary PCI
with thrombus aspiration group and in 86.53% falling under con-
ventional primary PCI group (p < 0.001). Also a trend was observed
indicating lower incidence of slow or no reﬂow in patients treated
with primary PCI with thrombus aspiration vis-a-vis conventional
primary PCI (3.84% vs 9.61%, p = 0.01). Complete resolution of ST-
segment elevation (>70% ST resolution) occurred in 59.34% and
46.12% patients, respectively (p < 0.005). Further analysis revealed
thatmortality beneﬁtwasnot conferredat 30 days (1.92%and3.84%,
p = 0.21) and 6months (3.84% and 7.69%, p = 0.13) in both the groups.
Conclusion: Our study showeda trend towards improvedmyocardial
perfusion (cTFC and ST segment resolution) with manual thrombus
aspiration during primary PCI as compared to conventional primary
PCI. However, mortality beneﬁt was not conferred with thrombus
aspiration when compared with conventional primary PCI.
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Background: First generation DES, including SES (Sirolimus eluting
stents), have signiﬁcantly reduced rates of re-stenosis and TLR
compared with BMS. But, at the same time, they have been found
to be associated with increased rates of late and very late stent
thrombosis, as well as MI. Improved stent designs with thinner
struts and more biocompatible polymer coatings and optimized
drug elution proﬁles (EES – everolimus-eluting stents) might favor-
ably inﬂuence DES performance. The aim to the study was to test
whether EES prevents clinical ischemic events better as compared
to SES.
Methods: We enrolled 120 patients with a diagnosis of ACS
(NSTEMI or STEMI) who had SVD (discrete lesion in culprit vessel)
on CAG over a 12-month period. Patients were assigned into EES or
SES group. Primary end points studied were CV Death and ACS;
Stent thrombosis and symptomatic in-stent re-stenosis (h/o
Chronic Stable Angina Post-PTCA +50% Late Lumen Loss on CAG).
Results: Incidence of CV death and ACS was 5% and 8.88% in EES
and SES group respectively ( p < 0.05), while that of Stent throm-
bosis was 3.33% and 6.66% ( p < 0.05). When studied in diabetic
subgroup, incidence of CV Death and ACS was 4% and 11.53%
( p < 0.05). Incidence of symptomatic ISR was 3.33% and 6.66% in
the two groups. In the diabetic subgroup, incidence of sympto-
matic ISR was 4% and 7.7%.
Conclusions: Our results support the hypothesis that the safe and
efﬁcacious platform of EES ismore effective in preventing ischemic
events (including stent thrombosis), and ISR than SES (1st genera-
tion DES). The results were in favor of EES when studied in context
of diabetic subgroup as well.
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Sirolimus-eluting stent (SES) is a ﬁrst-generation drug-eluting
stent (DES) and everolimus-eluting stent (EES) is a second genera-
tion drug-eluting stent. These both DES are widely used and most
extensively studied stents. Use of a DES substantially reduces
restenosis after coronary stent implantation; however, late
adverse events like stent thrombosis (ST) and late in-stent rest-
enosis (ISR) requiring target-lesion revascularization (TLR) occur-
ring beyond 1 year are still a problem. Similar outcomes have been
reported in various recent randomized trials comparing EES and
SES.
In this study, retrospective cohort study was done in the patients
who underwent stent implantation using SES or EES in Dhiraj
Hospital, Vadodara. Comparison between SES and EES was done
in patients who presented for follow-up in our cardiology depart-
ment over one year, i.e. May 2014 to May 2015 after their angio-
plasty. Based on angiographic and clinical outcome in terms of late
ST and ISR requiring TRL, outcome variables were set. The study
was carried out for evaluating non-inferiority of EES as compared
to SES in terms of late ST and ISR requiring TRL.
A total of 136 patients who underwent stent implantation using
SES or EES one to one and half year back agreed to be part of our
study and constituted our cohort. Out of these 136 patients, 60 had
SES implantation and 76 had EES implantation. All of these
patients were subjected to coronary angiography after 1 year to
look for patency of the stent. In-stent restenosis (outcome) was
found in 3 patients in SES group and 4 patients in EES group,
respectively.
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